Research Article
Mass Spectrometry in Clinical Diagnosis: A Preliminary Application in Tumor Cellular Proteomics for Biomarker Discovery
Ming-Hui Yang1,2,3†, Shyng-Shiou Yuan2,3,4,5, Yi-Ling Chen6†, Pei-Yu Chu7, Shiang-Bin Jong6,8, Ying-Fong Huang6,8, Chi-Yu Lu9,10, Yi-Shan Lu8, Po-Chiao Lin10,11 and Yu-Chang Tyan3,8,10,12*1Instrument Technology Research Center, National Applied Research Laboratories, Hsinchu, Taiwan
2Department of Medical Research, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
3Translational Research Center, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
4Department of Obstetrics and Gynecology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
5School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
6Department of Nuclear Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
7Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan
8Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan
9Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
10National Sun Yat-sen University-Kaohsiung Medical University Joint Research Center, Kaohsiung, Taiwan
11Department of Chemistry, National Sun Yat-sen University, Kaohsiung, Taiwan
12Center of Biomedical Engineering and System Biology, Kaohsiung Medical University, Kaohsiung, Taiwan
†These authors contributed equally to this work as first authors
- *Corresponding Author:
- Prof. Yu-Chang Tyan
Department of Medical Imaging and Radiological Sciences
Kaohsiung Medical University, 100
Shi-Chuan 1st Road, Kaohsiung 807, Taiwan
Tel: 886-7-3121101 ext 2357
E-mail: yctyan@kmu.edu.tw
Received date: January 27, 2014; Accepted date: February 19, 2014; Published date: February 21, 2014
Citation: Yang MH, Yuan SS, Chen YL, Chu PY, Jong SB, et al. (2014) Mass Spectrometry in Clinical Diagnosis: A Preliminary Application in Tumor Cellular Proteomics for Biomarker Discovery. J Anal Bioanal Tech S2:009. doi: 10.4172/2155-9872.S2-009
Copyright: © 2014 Yang MH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
is a group of diseases characterized by uncontrolled growth and spread of abnormal cells, which cause high mortality rates. The purpose of this study is to characterize the proteins secreted from the HepG2, MCF-7 and HT-29 cells, which may relate to cell differentiation and tumor metastasis. In the proteomic analysis, the secretome proteins were identified by reverse phase nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry (RP-nano-UPLC-ESI-MS/MS) followed by peptide fragmentation pattern analysis. Moreover, identifications of tumor cell protein expressions by proteomic approaches were indicated that several proteins may activate or enhance the PI3K/AKT/mTOR pathway. The PI3K/AKT/mTOR pathway has been shown to be related to the cancer cell metastasis and proliferation, and the ubiquitin C (UBC) may serve as potential protein diagnostic biomarker to be examined in further investigations.
